SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
SCYNEXIS (NASDAQ:SCYX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
SCYNEXIS (NASDAQ:SCYX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update